You look in the mirror and notice that the dark circles in the middle of your eyes are bigger than usual. What's going on? Those dark circles are your pupils, the openings that let light enter your ...

Mydriasis Market Outlook 2025-2035: The 7 major mydriasis market reached a value of USD 641.5 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,230.5 Million by 2035, ...

Vision – To be the world's leading and most trusted provider of information and services that will make a real difference in clinical practice and improve outcomes for patients. Mission – To lead the ...

Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Mydriasis - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. For the purpose of designing the patient-based ...

Pharmacologically-induced pupil dilation (mydriasis) can last up to 24 hours in adults and children with side effects such as sensitivity to light (photophobia) and blurred vision, which may make it ...

Eyenovia Inc (NASDAQ:EYEN) stock is trading higher on Thursday after its plunge yesterday, with a session volume of 6.7 million, versus an average volume of 1.33 as per data from Benzinga Pro. On ...

Viatris Inc., a global healthcare company, announced the US commercial launch of Ryzumvi (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by ...

This page lists all known medications that could potentially lead to 'Mydriasis' as a side effect. It's important to note that mild side effects are quite common with medications. The medication(s) ...

Viatris Inc., a global healthcare company, and Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved ...

The FDA has approved phentolamine ophthalmic solution (Ryzumvi) 0.75% for treatment-induced mydriasis, Viatris and Ocuphire Pharma announced. The approval stipulates use of the eye drops to manage ...

FARMINGTON HILLS, Mich., and PITTSBURGH, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and ...